Kymera Therapeutics KYMR Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's other income, net (note 6)?
- Kymera Therapeutics (KYMR) reported other income, net (note 6) of $14.92M in Q1 2026.
- How has Kymera Therapeutics's other income, net (note 6) changed year-over-year?
- Kymera Therapeutics's other income, net (note 6) increased by 68.7% year-over-year, from $8.85M to $14.92M.
- What is the long-term trend for Kymera Therapeutics's other income, net (note 6)?
- Over 4 years (2021 to 2025), Kymera Therapeutics's other income, net (note 6) has grown at a 232.0% compound annual growth rate (CAGR), from $313K to $38.05M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.